LONDON, Oct. 24, 2018 /PRNewswire/ -- The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.Download the full report: https://www.reportbuyer.com/product/5598600
What You Will Learn What approved immunotherapeutic drugs are indicated for self-administration, what is the as-supplied packaging, what are the device specifics, and who markets them? What are the major factors driving the migration of infusible immunotherapeutic drugs to formulations that can be packaged and administered subcutaneously? What is the size of the market for self-administered immunotherapeutic drugs today, who are the market share leaders, and what will the market share be in 2022? How important are drug developer-device manufacturer relationships and what are the key alliances in the industry? What are the essential design factors, technologies and market development issues for devices that can deliver injectable immunotherapeutics subcutaneously? What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?Download the full report: https://www.reportbuyer.com/product/5598600
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +1 (718) 213 4904 Website: www.reportbuyer.com
Advertisement
View original content:http://www.prnewswire.com/news-releases/immunotherapeutic-drugs-devices--patient-enablement-300737201.html
SOURCE ReportBuyer
